NEONC TECHNOLOGIES HOLDINGS, INC. Annual Report - How They Did This Year

I’ve put together this guide to help you understand NeOnc Technologies’ performance over the past year. My goal is to break down their updates so you can decide if this company fits your investment goals.

1. What does this company do?

NeOnc is a biotech company in the clinical testing phase. They are currently focused on developing new ways to treat aggressive brain cancers by overcoming the "blood-brain barrier," a natural defense that blocks medicine from reaching brain tumors. Their primary assets are NEO100, an intranasal treatment for recurrent brain cancer, and NEO212, an oral drug for primary and metastatic brain tumors.

2. Major Wins: Progress in the Lab

The company made significant scientific progress this year:

• NEO100: They expanded their clinical trials to include more types of brain cancer patients. This accelerated their timeline, and they now expect results by the end of 2024—a full year earlier than planned. Early data showed a 21% positive response rate, which compares favorably to the 8% historical benchmark for similar studies.
• NEO212: They completed the testing phase to determine the safest maximum dose for humans. They are now preparing to meet with the FDA to discuss Phase 2 testing, which will measure the drug's efficacy in extending patient survival.
• New Tech: They invested $3.5 million in new tools, including AI-driven drug discovery and 3D bioprinting. These investments are designed to shorten the drug development cycle by 18 months and reduce research costs by 15% over the next three years.

3. Financial Health: Still in "Spending Mode"

NeOnc is currently in a pre-revenue stage. They reported $0 in sales this year. Their operating expenses totaled $12.4 million, consisting of $8.2 million in research costs and $4.2 million in administrative fees. As of mid-2025, the company was valued at approximately $67.9 million. With $4.8 million in cash on hand, they are actively seeking non-dilutive funding, such as a potential $10 million partnership in the Gulf region, which would provide the runway needed to fund operations through late 2026.

4. Key Risks: What to Watch

Investing in this company carries significant risk. Consider the following factors:

• Clinical Success: The company’s value is tied to FDA approval. Because they have no other products to sell, their survival depends entirely on the success of their current trials.
• Dilution: To cover their $12.4 million annual operating expenses, the company has issued new shares. In the last year, they issued 1.2 million new shares, diluting existing shareholders by 9%. Future fundraising efforts may result in further dilution.
• Capital Requirements: With no current income or sales team, the company relies entirely on investors or licensing deals. Any delays in trial results could create a significant cash flow challenge.

5. Future Outlook

The focus for the coming year is to maintain momentum in their clinical trials. The company is targeting key results from their Phase 2 studies by the end of 2024. Additionally, they plan to leverage their new AI and 3D printing technology to build a pipeline of future treatments, with a goal to file at least one new drug application by Q3 2025.

Investor Takeaway: NeOnc is a high-stakes, early-stage biotech play. If you are considering an investment, weigh the potential of their clinical data against the reality that they are currently burning cash and will likely need to raise more capital before they can bring a product to market.